This is an experimental study (Interventional self-controlled trial, pretest-posttest design). The goal of this clinical trial is to evaluate the effect of vitamin D3 supplementation on quantitative EEG in male Parkinson's disease patients with hypovitaminosis D.
The main question it aims to answer is:
Vitamin D3 supplementation has effect on brain waves in male Parkinson's disease patients with hypovitaminosis D.
Researcher will compare the effect of vitamin D3 supplementation on brain waves in male Parkinson's disease patients with hypovitaminosis D with their pre intervention ( baseline ) condition on brain waves to assess whether there will be any improvement of brain electrical activity by quantitative electroencephalogram (QEEG).
Participants will :
Take vitamin D3 orally for 8 weeks (50,000 IU/week) Visit the medical university after 8 weeks for evaluation of serum 25(OH)D level and QEEG Must bring the empty strips of vitamin D supplement with them during their visit.
Male Patients with PD up to stage 3 according to Hoehn and Yahr (H-Y) scale
Age: 51years to70 years
BMI: 18.5-24.9 kg/m2
Hypovitaminosis D (Serum 25(OH)D level <30 ng/ml)
Already taking vitamin D3 supplements
Current use of medication/substances known to affect neuronal excitability or EEG patterns, such as - sedatives, antidepressant, antipsychotics, alcohol.
Patients who are currently suffering from following diseases
Neurological disorders (Migraine, epilepsy)
Single group
vitamin D3 capsule
Dietary supplementAdministration of vitamin D3 capsule 50,000 IU/week for 8 weeks
Change in absolute power in alpha, beta, theta, and delta frequency bands from baseline to 8 weeks
Measured using FFT-based quantitative EEG (qEEG) analysis. Unit of Measure: microvolts squared (µV²)
Change in relative power in alpha, beta, theta, and delta frequency bands from baseline to 8 weeks
Measured using FFT-based quantitative EEG (qEEG) analysis. Unit of Measure: percentage (%)
Change in peak power frequency in alpha, beta, theta, and delta bands from baseline to 8 weeks
Measured from global EEG spectrum using FFT-based qEEG analysis. Unit of Measure: Hertz (Hz)
Change in median power frequency from baseline to 8 weeks
Measured from global EEG spectrum using FFT-based qEEG analysis. Unit of Measure: Hertz (Hz)
Click on the lead sponsor to view all of their trials.
